Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/158112| Author(s): | Yoo, SGK Chung, GS Bahendeka, SK Sibai, AM Damasceno, A Farzadfar, F Rohloff, P Houehanou, C Norov, B Karki, KB Azangou-Khyavy, M Marcus, ME Aryal, KK Brant, LCC Theilmann, M Cífková, R Lunet, N Gurung, MS Mwangi, JK Martins, J Haghshenas, R Sturua, L Vollmer, S Bärnighausen, T Atun, R Sussman, JB Singh, K Saeedi Moghaddam, S Guwatudde, D Geldsetzer, P Manne-Goehler, J Huffman, MD Davies, JI Flood, D |
| Title: | Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries |
| Publisher: | American Medical Association |
| Issue Date: | 2023 |
| Abstract: | "Importance Aspirin is an effective and low-cost option for reducing atherosclerotic cardiovascular disease (CVD) events and improving mortality rates among individuals with established CVD. To guide efforts to mitigate the global CVD burden, there is a need to understand current levels of aspirin use for secondary prevention of CVD. Objective To report and evaluate aspirin use for secondary prevention of CVD across low-, middle-, and high-income countries. Design, Setting, and Participants Cross-sectional analysis using pooled, individual participant data from nationally representative health surveys conducted between 2013 and 2020 in 51 low-, middle-, and high-income countries. Included surveys contained data on self-reported history of CVD and aspirin use. The sample of participants included nonpregnant adults aged 40 to 69 years. Exposures Countries’ per capita income levels and world region; individuals’ socioeconomic demographics. Main Outcomes and Measures Self-reported use of aspirin for secondary prevention of CVD. Results The overall pooled sample included 124 505 individuals. The median age was 52 (IQR, 45-59) years, and 50.5% (95% CI, 49.9%-51.1%) were women. A total of 10 589 individuals had a self-reported history of CVD (8.2% [95% CI, 7.7%-8.6%]). Among individuals with a history of CVD, aspirin use for secondary prevention in the overall pooled sample was 40.3% (95% CI, 37.6%-43.0%). By income group, estimates were 16.6% (95% CI, 12.4%-21.9%) in low-income countries, 24.5% (95% CI, 20.8%-28.6%) in lower-middle-income countries, 51.1% (95% CI, 48.2%-54.0%) in upper-middle-income countries, and 65.0% (95% CI, 59.1%-70.4%) in high-income countries. Conclusion and Relevance Worldwide, aspirin is underused in secondary prevention, particularly in low-income countries. National health policies and health systems must develop, implement, and evaluate strategies to promote aspirin therapy." |
| DOI: | 10.1001/jama.2023.12905 |
| URI: | https://hdl.handle.net/10216/158112 |
| Source: | JAMA. 2023 Aug 22;330(8):715-724. doi: 10.1001/jama.2023.12905. |
| Document Type: | Artigo em Revista Científica Internacional |
| Rights: | restrictedAccess |
| Appears in Collections: | ISPUP - Artigo em Revista Científica Internacional |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| yoo-jama23-arcir.pdf Restricted Access | 695.59 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.